exhibited moderate activity against HeLa cells (IC50 = 42.8 µM). The molecular structures of 3h and 3i were solved by single crystal X-ray crystallographic technique. Additionally, the molecular docking studies between the tumour suppressor protein p53 with the lead compound 3h, which exhibited better anticancer activity against HeLa cells was examined.
合成了一系列的3-
苄基苯并
吡喃-4-酮,并通过M
TT法筛选了其抗癌活性。针对两种癌
细胞系BT549(人类乳腺癌),HeLa(人类宫颈癌)和一种非癌
细胞系vero(正常肾脏上皮细胞)对化合物进行了评估。发现3b是对抗
BT549细胞(IC 50 = 20.1 µM)最活跃的分子,而3h是对抗HeLa细胞(IC 50 = 20.45 µM)最活跃的分子。3b还显示出对HeLa细胞的中等活性(IC 50 = 42.8 µM)。3h和3i的分子结构通过单晶X射线晶体学技术解决。此外,检查了在肿瘤抑制蛋白p53与先导化合物3h之间的分子对接研究,该化合物对HeLa细胞表现出更好的抗癌活性。